-
2024-515162-13-00
5
2025-04-29
Eosinophilic Asthma
-
2024-514465-18-00
9
2025-04-23
Advanced or Metastatic Non-Squamous NSCLC
-
2024-517284-23-00
5
2025-04-23
Active Psoriatic Arthritis
-
2024-513053-69-00
5
2025-04-16
Moderately to Severely Active Crohn's Disease (CD)
-
2023-504904-26-00
5
2025-04-07
Progressive Pulmonary Fibrosis
-
2022-501489-24-00
5
2025-03-28
First-line treatment of adult subjects with high-risk large B-cell lym
-
2023-509806-31-00
4
2025-02-11
Non-Small Cell Lung Cancer
-
2022-502352-31-00
5
2025-02-10
Colorectal Cancer (CRC)
-
2024-512900-20-00
7
2025-01-30
Non-muscle invasive bladder cancer (NMIBC)
-
2023-503675-24-00
5
2025-01-17
Triple-negative Breast Cancer
-
2023-505868-11-00
5
2025-01-17
CHRONIC RENAL DISEASE
-
2024-513004-33-00
4
2025-01-14
Hepatotoxicity
-
2024-519969-21-00
6
2025-01-01
Infective endocarditis
-
2024-511596-15-00
4
2024-12-26
Liver Diseases, Alcoholic
-
2024-511188-26-00
5
2024-12-20
Relapsed/refractory multiple myeloma in patients who have received 1 t
-
2023-509717-36-00
5
2024-12-16
AF patients who have undergone successful PCI
-
2023-510150-17-00
4
2024-12-11
Active, refractory systemic lupus erythematosus (SLE), and active, re
-
2023-510380-34-00
4
2024-12-10
Diffuse cutaneous systemic sclerosis (dcSSc)
-
2023-508191-11-00
5
2024-11-28
Systemic lupus erythematosus (SLE)
-
2024-512279-10-00
5
2024-11-25
Triple Negative Breast Cancer
-
2024-512895-36-00
5
2024-11-25
Metabolic Dysfunction-Associated Steatohepatitis (MASH)
-
2024-512835-53-00
4
2024-11-20
Diffuse Large B-Cell Lymphoma
-
2023-505232-36-00
5
2024-11-15
Essential thrombocythemia
-
2024-516011-24-01
4
2024-11-13
Cytomegalovirus infection in allogeneic stem cell transplant recipient